EyePoint Pharma Appoints Dr. Guyer CEO, Miller Departs Board
Ticker: EYPT · Form: 8-K · Filed: Sep 4, 2024 · CIK: 1314102
| Field | Detail |
|---|---|
| Company | Eyepoint Pharmaceuticals, Inc. (EYPT) |
| Form Type | 8-K |
| Filed Date | Sep 4, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $45,000, $5,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-appointment, board-departure
TL;DR
Guyer officially CEO at EyePoint, $500k salary. Miller out.
AI Summary
EyePoint Pharmaceuticals, Inc. announced on September 3, 2024, the appointment of Dr. David R. Guyer as Chief Executive Officer and a member of the Board of Directors. Dr. Guyer, who previously served as interim CEO, will receive an annual base salary of $500,000 and is eligible for a performance-based bonus. The company also reported the departure of Dr. Joan W. Miller from the Board of Directors.
Why It Matters
The appointment of a permanent CEO signals a new leadership direction for EyePoint Pharmaceuticals, potentially impacting its strategic focus and operational execution. Dr. Miller's departure may also indicate shifts in board composition or governance.
Risk Assessment
Risk Level: medium — Leadership changes and board departures can introduce uncertainty regarding future strategy and stability.
Key Numbers
- $500,000 — CEO Annual Base Salary (Dr. David R. Guyer's compensation as new CEO.)
Key Players & Entities
- EyePoint Pharmaceuticals, Inc. (company) — Registrant
- Dr. David R. Guyer (person) — Appointed CEO and Board Member
- $500,000 (dollar_amount) — Dr. Guyer's annual base salary
- Dr. Joan W. Miller (person) — Departed Board of Directors
- September 03, 2024 (date) — Date of earliest event reported
FAQ
What is Dr. David R. Guyer's new role at EyePoint Pharmaceuticals?
Dr. David R. Guyer has been appointed as the Chief Executive Officer and a member of the Board of Directors of EyePoint Pharmaceuticals, Inc.
What is Dr. Guyer's annual base salary?
Dr. Guyer's annual base salary is $500,000.
Who has departed from the Board of Directors?
Dr. Joan W. Miller has departed from the Board of Directors.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on September 03, 2024.
What was EyePoint Pharmaceuticals' former company name?
EyePoint Pharmaceuticals, Inc. was formerly known as pSivida Corp. and pSivida LTD.
Filing Stats: 977 words · 4 min read · ~3 pages · Grade level 9.7 · Accepted 2024-09-04 07:05:30
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Ind
- $45,000 — will receive an annual cash retainer of $45,000 for his Board service, which amount wil
- $5,000 — e an additional annual cash retainer of $5,000 for his service as a member of the Gove
Filing Documents
- eypt-20240903.htm (8-K) — 45KB
- eypt-ex99_1.htm (EX-99.1) — 23KB
- img96707757_0.jpg (GRAPHIC) — 5KB
- 0000950170-24-103097.txt ( ) — 191KB
- eypt-20240903.xsd (EX-101.SCH) — 23KB
- eypt-20240903_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On September 4, 2024, the Company issued a press release announcing the resignations of Dr. Guyer and Dr. Adamis and the appointment of Mr. Hassan to the Board. A copy of the press release is filed with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated by reference to this Item 8.01.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release of EyePoint Pharmaceuticals, Inc. dated September 4, 2024 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYEPOINT PHARMACEUTICALS, INC. Date: September 4, 2024 By: /s/ George O. Elston George O. Elston Executive Vice President and Chief Financial Officer